Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Atherosclerosis is the major cause of morbidity and mortality worldwide. Endothelial dysfunction is central to the pathogenesis of atherosclerosis, initiating a triad of lipid accumulation in the vessel wall, a co-existent inflammatory response and proliferation of smooth muscle cells. It has also been implicated in the precipitation of acute ischaemia, and the determination of the extent of injury following such complications. Healthy endothelium regulates numerous blood vessel functions, including vascular tone, cell adhesiveness, and coagulation through the production of mediators. The best characterised of these are the vasodilators, nitric oxide (NO), prostacyclin, and endothelium derived hyperpolarising factor, and the vasoconstrictors thromboxane and endothelin. The endothelium itself may also be maintained by bone-marrow derived endothelial progenitor cells (EPC) which are mobilised in response to vascular injury and have angiogenic and proliferative properties. Understanding of the biology of the endothelium in atherosclerosis has led to new treatments and more may follow. Work is ongoing into NO bioavailability, prostacyclin agonists, endothelin and thromboxane antagonists, novel antiinflammatory and anti-oxidative agents as well as means of harnessing the properties of EPCs. It is hoped that this research will yield clinically useful approaches that will retard the progression of atherosclerosis and reduce the incidence or consequences of acute complications. © 2012 Bentham Science Publishers.

Original publication

DOI

10.2174/187152212803521011

Type

Journal article

Journal

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Publication Date

03/12/2012

Volume

12

Pages

279 - 288